Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.

The present invention relates to a crystalline form of a free base of a compound of formula (A) (compound A) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use of the compound in the preparation of a medicament for treating and/or preventing diseases mediated by ALK kinase and mutants thereof, such as cell proliferative diseases, inflammation, infections, immunological diseases, organ transplantation, viral diseases, cardiovascular diseases or metabolic diseases.

##STR00001##

A press coated tablet for delayed release of an active ingredient comprising: (a) a core comprising one or more active ingredients, and; (b) an erodible delayed release barrier surrounding the core and comprising a wax and two or more grades of L-HPC, wherein the wax and L-HPC are provided in a weight ratio of wax to L-HPC of from 30%:70% to 70%:30%. The invention also relates to a method of making the press coated tablet.

A process for producing an esterified cellulose ether comprises the step of reacting a cellulose ether with an aliphatic monocarboxylic acid anhydride and/or a dicarboxylic acid anhydride and with a depolymerizing agent, wherein the cellulose ether has an initial viscosity of at least 500 mPa.Math.s, measured as a 2 weight-% solution in water at 20° C., and the reaction of the cellulose ether with the aliphatic monocarboxylic acid anhydride and/or the dicarboxylic acid anhydride and with the depolymerizing agent is conducted simultaneously or in sequence in one reaction device.

A process for producing a cellulose ether acetate succinate comprises the step of reacting a cellulose ether with acetic anhydride, succinic anhydride and an depolymerizing agent, wherein the cellulose ether has an initial viscosity of at least 50 mPa-s, measured as a 2 weight-% solution in water at 20° C., and the reaction of the cellulose ether with acetic anhydride, succinic anhydride and the depolymerizing agent is conducted simultaneously or in sequence in one reaction device.

The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.

The present invention relates to a new type of eutectic crystal of lorcaserin hydrochloride and benzoic acid. Compared with the prior art, the eutectic crystal has the improved properties of good stability, low solubility, and being suitable for the application of controlled-release preparation. The present invention also relates to a method for preparing the eutectic crystal, a pharmaceutical composition thereof and the use thereof in the manufacture of drugs for treating and/or preventing diseases associated with 5HT.sub.2C.

The present invention relates to a systemic formulation, in particular an oral formulation, for the prophylaxis and/or treatment of coeliac disease, i.e. for use in the prophylaxis and/or treatment of coeliac disease.